Formulations and methods for modulating satiety

• US 20080069869A1
• Filed: 03/30/2007
• Published: 03/20/2008
• Est. Priority Date: 08/23/2004
• Status: Abandoned Application

• Current Assignee: Rose Pharmaceuticals, LLC
• Original Assignee: Rose Pharmaceuticals, LLC
• Inventors: Rosenberg, Mark
• Application Number:
  US11/731,166
• Publication Number:
  US 20080069869A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 38/2207 Gastrins; Cholecystokinins [CCK]
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/4891 Coated capsules; Multilayered drug free capsule shells with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

Formulations and methods of suppressing appetite and eliciting satiety in mammals are described. In some embodiments, oral administration of an effective amount of an appetite-suppressing peptide, in a composition that increases the bioavailability of the appetite-suppressing peptide, are effective to produce a feeling of satiety.

Claims

1. A pharmaceutical formulation for oral administration to a patient effective to reduce feeding in a patient, comprising:

an appetite-suppressing peptide; and

at least one chelating agent;

wherein at least one of the appetite-suppressing peptide and the at least one chelating agent is encased in an enteric protectant; and

wherein the combination of the chelating agent and enteric protectant is effective to increase the bioavailability of the appetite-suppressing peptide.

2. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is effective to increase satiety.

3. The pharmaceutical formulation of claim 1, further comprising one or more acceptable carriers.

4. The pharmaceutical formulation of claim 1, wherein the enteric protectant is an enteric coating or capsule.

5. The pharmaceutical formulation of claim 1, wherein the appetite-suppressing peptide comprises at least one of a CCK or caerulein.

6. The pharmaceutical formulation of claim 5, wherein the CCK is provided at a dosage of between about 0.1 ug and 40 ug per day.

7. The pharmaceutical formulation of claim 1, wherein the CCK is provided at a dosage effective to result in blood circulating levels of CCK of at least about 3 pmol/L within 20 minutes after administration.

8. The pharmaceutical formulation of claim 1, wherein the CCK is provided at a dosage effective to results in blood circulating levels of CCK in a range of between about 4 pmol/L and 8 pmol/L, within 20 minutes after administration.

9. The pharmaceutical formulation of claim 5, wherein the caerulein is provided at a dosage of between about 0.05 and 20 ug per day.

10. The pharmaceutical formulation of claim 5, where the CCK is selected from the group consisting of cholecystokinin-8 (CCK-8), N-sarkosyl-CCK-8, N-taurine-CCK-8, N-pyroglutamic-CCK-8, C-terminal heptapeptide of CCK (CCK-7), N-sarkosyl-CCK-7, N-taurine-CCK-7, N-pyroglutamic-CCK-7, t-BOCK-CCK-7 and cholecystokinin-4 (CCK-4).

11. The pharmaceutical formulation of claim 1, wherein the chelating agent is selected from the group consisting of:

ethylenediamine-N,N,N′

,N′

-tetraacetic acid (EDTA);

the disodium, trisodium, tetrasodium, dipotassium, tripotassium, dilithium and diammonium salts of EDTA;

the barium, calcium, cobalt, copper, dysprosium, europium, iron, indium, lanthanum, magnesium, manganese, nickel, samarium, strontium, and zinc chelates of EDTA;

trans-1,2-diaminocyclohexane-N,N,N′

,N′

-tetraaceticacid monohydrate;

N,N-bis(2-hydroxyethyl)glycine;

1,3-diamino-2-hydroxypropane-N,N,N′

,N′

-te-traacetic acid;

1,3-diaminopropane-N,N,N′

,N′

-tetraacetic acid;

ethylenediamine-N,N′

-diacetic acid;

ethylenediamine-N,N′

-dipropionic acid dihydrochloride;

ethylenediamine-N,N′

-bis(methylenephosphonic acid) hemihydrate;

N-(2-hydroxyethyl)ethylenediamine-N,N′

,N′

-triacetic acid;

ethylenediamine-N,N,N′

,N′

-tetrakis(methylenephosphonic acid);

O,O′

-bis(2-aminoethyl)ethyleneglycol-N,N,N′

,N′

-tetraacetic acid;

N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid;

1,6-hexamethylenediamine-N,N,N′

,N′

-tetraacetic acid;

N-(2hydroxyethyl)iminodiacetic acid;

iminodiacetic acid;

1,2-diaminopropane-N,N,N′

,N′

-tetraacetic acid;

nitrilotriacetic acid;

nitrilotripropionic acid;

the trisodium salt of nitrilotris(methylenephos-phoric acid);

7,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo[11,11,11]pentatriacontane hexahydrobromide; and

triethylenetetramine-N, —

N,N′

,N″

,N′

″

,N′

″

-hexaacetic acid, citric acid, and phosphoric acid.

12. The pharmaceutical formulation of claim 11, wherein the chelating agent comprises citric acid.

13. The pharmaceutical formulation of claim 12, wherein citric acid is present in an amount effective to bring the pH of the formulation within a range from about 1.5 to about 3.0.

14. The pharmaceutical formulation of claim 1, further comprising a lipid-based delivery system.

15. The pharmaceutical formation of claim 14, where the lipid-based drug delivery system comprises liposomes.

16. The pharmaceutical formulation of claim 1, wherein the formulation is provided in the form of nanoparticles.

17. The pharmaceutical formulation of claim 1, further comprising a permeation enhancer, effective to increase transport of the appetite-suppressing peptide across the intestinal epithelium.

18. The pharmaceutical formulation of claim 17, wherein the permeation enhancer comprises at least one of oleate, palmitate, stearate, caprate, a conjugated linoleic acid, bile salts, or sterylglucoside.

19. The pharmaceutical formulation of claim 1, further comprising a bioactive substance, effective to enhance the therapeutic effect of the appetite-suppressing peptide.

20. The pharmaceutical formulation of claim 19, wherein the bioactive substance comprises at least one of:

an epinephrine antagonist, an opiate antagonist, a pancreatic polypeptide blocker, a GABA agonist, a serotonin agonist, a calcitonin agonist, a corticotrophin-releasing factor agonist, a neurotensin agonist, a dopamine agonist, an anaesthetic, a glucagons agonist, pro-opiomelanocortin, cocaine- and amphetamine-regulated transcript (CART), urotcortin, thyrotropin-releasing hormone, galanin-like peptide-1, peptide YY, ciliary neurotrophic factor, brain-derived neural factor, insulin, insulin-like growth factor-1, insulin-like growth factor-2, leptin, neuropeptide K, calcitonin-gene-related peptide, prolactin-releasing peptide, neuromedin, neuropeptide B, somatostatin, oxytocin, bombesin, motilin, enterostatin, anorectin, amylin, or interleukin 1.

21. The pharmaceutical formulation of claim 1, further comprising a estrogenic hormone therapy composition.

22. The pharmaceutical formulation of claim 21, wherein the estrogenic hormone therapy composition comprises a birth control composition.

23. The pharmaceutical formulation of claim 21, wherein the estrogenic hormone therapy composition comprises an estrogen replacement composition.

24. The pharmaceutical formulation of claim 21, wherein the estrogenic hormone therapy composition comprises a selective estrogen receptor modulator.

25. The pharmaceutical formulation of claim 24, wherein the selective estrogen receptor modulator is at least one of raloxifene, lasofoxifene, bazedoxifene, clomifene, tamoxifen, toremifene, or ormeloxifene.

26. A method of reducing feeding in a patient comprising:

providing a pharmaceutical formulation, comprising;

an appetite-suppressing peptide and at least one chelating agent;

wherein the pharmaceutical formulation is encased in an enteric protectant, and wherein the combination of the chelating agent and enteric protecting is effective to increase the bioavailability of the appetite-suppressing peptide; and

administering the pharmaceutical formulation to the patient.

27. The method of claim 26, wherein administration of the pharmaceutical formulation increases satiety.

28. The method of claim 26, wherein the pharmaceutical formulation further comprises one or more acceptable carriers.

29. The method of claim 26, wherein said appetite-suppressing peptide comprises at least one of a CCK or caerulein.

30. The method of claim 29, wherein CCK is provided at a dosage of between about 0.1 ug and 40 ug per day.

31. The method of claim 26, wherein the dosage of the pharmaceutical formulation administered is effective to result in blood circulating levels of CCK of at least 3 pmol/L within 20 minutes after administration.

32. The method of claim 26, wherein the dosage of the pharmaceutical formulation administered is effective to result in blood circulating levels of CCK in a range of between about 4 pmol/L and about 20 pmol/L within 20 minutes after administration.

33. The method of claim 29, wherein caerulein is provided at a dosage of between about 0.05 and 20 ug per day.

34. The method of claim 29, where the CCK is selected from the group consisting of:

cholecystokinin-8 (CCK-8), N-sarkosyl-CCK-8, N-taurine-CCK-8, N-pyroglutamic-CCK-8, C-terminal heptapeptide of CCK (CCK-7), N-sarkosyl-CCK-7, N-taurine-CCK-7, N-pyroglutamic-CCK-7, t-BOCK-CCK-7 or cholecystokinin-4 (CCK-4).

35. The method of claim 26, wherein the chelating agent is selected from the group consisting of:

ethylenediamine-N,N,N′

,N′

-tetraacetic acid (EDTA);

the disodium, trisodium, tetrasodium, dipotassium, tripotassium, dilithium and diammonium salts of EDTA;

the barium, calcium, cobalt, copper, dysprosium, europium, iron, indium, lanthanum, magnesium, manganese, nickel, samarium, strontium, and zinc chelates of EDTA;

trans-1,2-diaminocyclohexane-N,N,N′

,N′

-tetraaceticacid monohydrate;

N,N-bis(2-hydroxyethyl)glycine;

1,3-diamino-2-hydroxypropane-N,N,N′

,N′

-te-triacetic acid;

1,3-diaminopropane-N,N,N′

,N′

-tetraacetic acid;

ethylenediamine-N,N′

-diacetic acid;

ethylenediamine-N,N′

-dipropionic acid dihydrochloride;

ethylenediamine-N,N′

-bis(methylenephosphonic acid) hemihydrate;

N-(2-hydroxyethyl)ethylenediamine-N,N′

,N′

-triacetic acid;

ethylenediamine-N,N,N′

,N′

-tetrakis(methylenephosphonic acid);

O,O′

-bis(2-aminoethyl)ethyleneglycol-N,N,N′

,N′

-tetraacetic acid;

N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid;

1,6-hexamethylenediamine-N,N,N′

,N′

-tetraacetic acid;

N-(2-hydroxyethyl)iminodiacetic acid;

iminodiacetic acid;

1,2-diaminopropane-N,N,N′

,N′

-tetraacetic acid;

nitrilotriacetic acid;

nitrilotripropionic acid;

the trisodium salt of nitrilotris(methylenephos-phoric acid);

7,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo[11,11,11]pentatriacontane hexahydrobromide; and

triethylenetetramine-N, —

N,N′

,N″

,N′

″

,N′

″

-hexaacetic acid, citric acid, and phosphoric acid.

36. The method of claim 26, wherein the pharmaceutical formulation further comprises a bioactive substance operative to enhance the therapeutic effect of the appetite-suppressing peptide.

37. The method of claim 36, wherein the bioactive substance is at least one of:

an epinephrine antagonist, an opiate antagonist, a pancreatic polypeptide blocker, a GABA agonist, a serotonin agonist, a calcitonin agonist, a corticotrophin-releasing factor agonist, a neurotensin agonist, a dopamine agonist, an anaesthetic, a glucagons agonist, pro-opiomelanocortin, cocaine- and amphetamine-regulated transcript (CART), urotcortin, thyrotropin-releasing hormone, galanin-like peptide-1, peptide YY, ciliary neurotrophic factor, brain-derived neural factor, insulin, insulin-like growth factor-1, insulin-like growth factor-2, leptin, neuropeptide K, calcitonin-gene-related peptide, prolactin-releasing peptide, neuromedin, neuropeptide B, somatostatin, oxytocin, bombesin, motilin, enterostatin, anorectin, amylin, or interleukin 1.

38. The method of claim 26, further comprising administering a volume of liquid prior to the pharmaceutical formulation in order to improve the effectiveness of the pharmaceutical formulation.

39. The method of claim 26, wherein the volume of liquid is administered about 60 minutes, or less, prior to administration of the pharmaceutical formulation.

40. The method of claim 39, wherein the volume of liquid is administered from about 10 minutes to about 20 minutes prior to administration of the pharmaceutical formulation.

41. The method of claim 26, wherein the pharmaceutical formulation is administered to an individual who is also engaged in an estrogenic hormone therapy.

42. The method of claim 41, wherein the pharmaceutical formulation is administered simultaneously with the estrogenic hormone therapy.

43. The method of claim 41, wherein the pharmaceutical formulation is administered sequentially with the estrogenic hormone therapy.

44. The method of claim 41, wherein the estrogenic hormone therapy comprises administration of estrogen in the form of a birth control pill.

45. The method of claim 41, wherein the estrogenic hormone therapy comprises an estrogen replacement therapy.

46. The method of claim 41, wherein the estrogenic hormone therapy comprises administration of a selective estrogen receptor modulator.

47. The method of claim 41, wherein the selective estrogen receptor modulator comprises at least one of raloxifene, lasofoxifene, bazedoxifene, clomifene, tamoxifen, toremifene, and ormeloxifene.